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A new antibiotic with potent activity targets MscL
Irene Iscla1, Robin Wray1, Paul Blount1, Jonah Larkins-Ford2, Annie L Conery2, Frederick M Ausubel2,
Soumya Ramu3, Angela Kavanagh3, Johnny X Huang3, Mark A Blaskovich3, Matthew A Cooper3,
Andres Obregon-Henao4, Ian Orme4, Edwin S Tjandra5, Uwe H Stroeher6, Melissa H Brown6,
Cindy Macardle7, Nick van Holst7, Chee Ling Tong8, Ashley D Slattery8, Christopher T Gibson8,
Colin L Raston8 and Ramiz A Boulos8
The growing problem of antibiotic-resistant bacteria is a major threat to human health. Paradoxically, new antibiotic discovery
is declining, with most of the recently approved antibiotics corresponding to new uses for old antibiotics or structurally similar
derivatives of known antibiotics. We used an in silico approach to design a new class of nontoxic antimicrobials for the
bacteria-speciﬁc mechanosensitive ion channel of large conductance, MscL. One antimicrobial of this class, compound 10, is
effective against methicillin-resistant Staphylococcus aureus with no cytotoxicity in human cell lines at the therapeutic
concentrations. As predicted from in silico modeling, we show that the mechanism of action of compound 10 is at least partly
dependent on interactions with MscL. Moreover we show that compound 10 cured a methicillin-resistant S. aureus infection in
the model nematode Caenorhabditis elegans. Our work shows that compound 10, and other drugs that target MscL, are
potentially important therapeutics against antibiotic-resistant bacterial infections.
The Journal of Antibiotics (2015) 68, 453–462; doi:10.1038/ja.2015.4; published online 4 February 2015
INTRODUCTION
The overprescription of antibiotics and failure of patients to complete
antibiotic treatment regimens have contributed to the emergence of
bacterial multi-drug resistance (MDR). At the same time, the large
costs involved in developing new drugs, exacerbated by a complicated
drug approval and patent process,1 have caused a dearth in new
antibiotic research with many pharmaceutical companies choosing to
focus their efforts on more proﬁtable, higher volume drugs.2,3 As a
result, ﬁghting MDR bacterial infections in patients is becoming
increasingly difﬁcult with treatment options becoming very limited.4,5
Furthermore, there are relatively few novel small molecules in the
antibiotic development pipeline.6
The mechanosensitive ion channel of large conductance (MscL) in
bacteria is an attractive target for drug discovery because of its high
level of conservation in bacterial species, and its absence from the
human genome. Such level of conservation suggests that the channel
has an important and conserved function, which has recently been
highlighted as one of the top 20 targets for drug development.7 In
Escherichia coli, the transmembrane MscL channel consists of ﬁve
identical subunits, each composed of 136 amino acids.8,9 MscL has the
largest pore size of any gated ion channel, estimated to be 28 Å when
fully open.10,11 Mechanosensitive channels have evolved to sense
mechanical tension on the membrane and convert it into an
electrochemical response. As such, they act as gatekeepers, protecting
bacterial cells against lysis following acute decrease in the osmotic
environment. Moreover, these channels can act as entry points for
drugs and other small molecules into bacterial cells.
In this paper, we describe the in silico design of MscL ligands, which
led to the discovery of a novel class of compounds with optimal
binding to MscL. One of these ligands, 1,3,5-tris[(1E)-2′-(4″-benzoic
acid)vinyl]benzene (referred to hereafter as 10, Ramizol), is an
effective antimicrobial against methicillin-resistant Staphylococcus aur-
eus (MRSA).12 Using microscopic analysis and other techniques, we
show that the mechanism of action of 10 in Gram-positive and Gram-
negative bacteria involves its interaction with MscL. We also show that
10 exhibits in vivo efﬁcacy in a Caenorhabditis elegans nematode
infection model. Moreover, 10 exhibits low levels of toxicity in
addition to being a potent antioxidant,13 potentially providing an
additional beneﬁt by reducing bacterial-induced inﬂammation.
RESULTS
In silico design of ligands targeting MscL
To explore the potential of MscL as a target for antibiotics, we
developed a spatial map between the exposed oxygen atoms of amino
acids, lining the gate of the MscL channel. This three-dimensional
spatial map was used for the de novo design14 of several potential
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ligands capable of hydrogen bonding to the MscL channel amino acids
as shown in Figure 1a. We calculated that one of these potential
ligands, 1,2,4-tris[2′-(4″-phenol)ethyl]benzene (ligand 2), had the
lowest docking energy (Figure 1b). We then further optimized the
binding of ligand 2 using iterative in silico docking models to identify
related structures with lower docking energies (Figure 1c). Speciﬁcally,
the hydroxyl groups in ligand 2 were substituted with a variety of
functional groups (aldehydes, amide cations, amino, carboxyl, chlor-
ide). With reference to Figure 1c, we found that the addition of
carboxyl groups to the ‘b’, ‘c’ and ‘d’ positions resulted in the most
favorable docking energies. This ligand, 8, was determined to have a
free energy of binding equivalent to ~− 55.94 kJ mol− 1, which is
higher than previously screened candidates from the National Cancer
Institute database. Thus, compound 8 and its analogs represent a
potentially novel class of antimicrobials based on p-carboethoxy-
tristyryl and p-carboethoxy-terastyrenyl benzene derivatives.
Compound 10 is a potent antibiotic against a range of Gram-
positive bacteria
We further investigated a particular analog of compound 8: the
symmetrical and ﬂuorescent molecule 10, which, based on preliminary
disk diffusion studies, was found to be more effective than the
other analogs12 with the exception of 2,2′,2″-{[(1E,1′E,1″E)-benzene-
1,3,5-triyltris(ethene-2,1-diyl)]tris(benzene-4,1-diyl)}triacetic acid, 11,
which was only discovered recently.15 As shown in Table 1, 10 is a
potent antimicrobial against a variety of S. aureus strains with
minimum ICs (MICs) of ~ 4 μg ml− 1. These S. aureus strains include
a variety of drug-resistant MRSA, glycopeptide intermediate S. aureus
(GISA) and vancomycin-resistant S. aureus (VRSA) strains, including a
MRSA strain that is daptomycin-resistant. 10 was also effective against
an MDR Streptococcus pneumoniae strain with a MIC of 4 μgml− 1. In
contrast, 10 was relatively inactive (MIC 464 μg ml− 1) against
Enterococcus faecalis VanA clinical isolate and E. faecium MDR-VanA
ATCC 51559. 10 was also inactive against a variety of Gram-negative
bacteria tested (E. coli ATCC 25922, Klebsiella pneumoniae ATCC
700603, K. pneumoniae ATCC 13883, Acinetobacter baumannii ATCC
19606 and Pseudomonas aeruginosa ATCC 27853) with an MIC464-
μgml− 1 (data not shown), but showed marginal activity against a
P. aeruginosa polymyxin–resistant strain (MIC 64 μg ml− 1) and a
K. pneumoniae BAA-2146 NDM-1-positive strain (MIC 64 μgml− 1).
Compound 10 also showed no signiﬁcant activity against
M. tuberculosis strains H37Rv and TT372 grown in 7H9 medium
(MIC 160 μg ml− 1). However, when H37Rv was grown in Proskauer
and Beck medium or in glycerol-alanine-salts media, the MIC was
20 μg ml− 1 (Table 1). One possible explanation for this observation is
that the 7H9 medium contains albumin. It is well established that high
afﬁnity of albumin to a wide range of structurally different drugs16 can
affect their bioavailability. If 10 does indeed bind to albumin,
Figure 1 (a) Diagrammatic representation of target amino acids Leu19, Ala20 and Val23 in close proximity to the E. coli MscL channel gate, which
were used for the de novo design of the designated ligands. (b) Docking energies (kcal mol−1) of the ligands. (c) Iterative in silico docking of lead ligand 2,
which gave rise to new class of antimicrobials including compounds 8–12. A full color version of this ﬁgure is available at The Journal of Antibiotics
journal online.
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it suggests that the structure of 10 may be further optimized to
increase its bioavailability. For a detailed chart, see Supplementary
Figure S1.
Compound 10 toxicity
We measured the cytotoxicity of 10 against a number of human tissue
culture cell lines. The growth of NIH/3T3 and HaCaT cells was not
affected by 50 μg ml− 1 of 10, and at 100 μgml− 1 only a marginal
effect on growth was observed, whereas 500 μg ml− 1 of 10 completely
blocked the growth of these cells (Supplementary Figures S2a and b).
Testing for 24 h on other cell lines such as HepG2 and HEK293
revealed no cytotoxicity up to 50 μg ml− 1 of 10 (Supplementary
Figures S2c and d). Therefore toxicity to eukaryotic cells is not seen
until ~ 10 times the MIC against S. aureus.
Compound 10 acts through MscL
As 10 was speciﬁcally designed as a ligand for MscL, we sought
evidence that the antimicrobial activity of 10 is a consequence of its
interaction with the MscL channel. Even though 10 is not as effective
against some Gram-negative species and strains, we reasoned that if
the particular parental E. coli strain (FRAG-1) that was used to
generate all of the mechanosensitive channel null strains was sensitive
enough to 10, we should be able to determine whether the potency of
10 is dependant on MscL. We therefore tested these strains. In
addition, a variety of genetic and physiological tools are readily
available in E. coli for the analysis of mechanosensitive channels
making it the organism of choice for such experiments.
Growth inhibition assays of 10 were performed using E. coli
MJF61217 carrying an empty vector, expressing wild-type E. coli MscL
(Eco MscL), expressing a MscL K55T mutant that is slightly more
sensitive to tension,9 expressing the MscL orthologues from Clostri-
dium perﬁngens (CP MscL), or expressing the MscL orthologue from
S. aureus (SA MscL). For concentrations of 10 in the 7.5–10 μgml− 1
range, all strains expressing mscL except the mscL homolog from
S. aureus showed reduced growth in a pilot-experiment titration curve
compared with the control strain carrying the empty vector
(Figure 2a). These data suggest that at concentrations of ~ 7.5 μgml− 1,
MscL is required for the mediated growth inhibition of 10. In contrast,
at ~ 16.5 μgml− 1, all strains were equally inhibited, suggesting that
MscL is not the only target of 10 at concentrations greater than this
concentration.
In a separate experiment, E. coli MJF612 expressing various mscL
genes was grown to stationary phase in the presence of 13.5 μgml− 1 of
10. E. coli MJF612 expressing the unrelated E. coli mechanosensitive
channel of small conductance (MscS), which also detects membrane
tension, was included to examine whether 10 has speciﬁcity for MscL.
Cells expressing Eco MscL, Eco K55T MscL and C. perfringens MscL
showed a decreased growth dependant on 10, whereas cells containing
an empty vector and those expressing SA MscL showed growth
independent of 10 (Figure 2b). Bacteria expressing MscS were also
sensitive to 10, however the decrease in growth rate observed for the
E. coli expressing MscS was only half of the strain expressing MscL.
The observation that expression of SA MscL in E. coli does not confer
sensitivity to 10 may not be surprising given that SA MscL is more
difﬁcult to gate when in E. coli membrane compared with being in its
native membranes.18 This is possibly due to the requirement
of S. aureus endogenous lipid composition much like for the
M. tuberculosis MscL.19 These data show that MscL, and to a lesser
extent MscS expression, affect the efﬁcacy of the drug.
To determine whether 10 directly affects the activity of the MscL
channel, we carried out patch-clamp experiments of native mem-
branes using an E. coli ‘giant’ spheroplast preparation derived from
strain PB104 (an mscL null mutant in which Eco MscL is over-
expressed to enhance the number of channel activities observed20).
The response of MscL to pressure across the patch was assessed before
and after treatment with 25 μgml− 1 of 10. As shown in Figure 2c,








S. aureus MRSA DapRSA
clinical isolate
S. aureus GISA, MRSA
NRS 1
S. pneum MDR ATCC
700677
Vancomycin 1 1 4 2 4 1
Compound 10 8 8 4 4 4 4
Compound S. aureus NARSA VRS 3b S. aureus NARSA VRS 4 S. aureus NARSA VRS 1 S. aureus NARSA VRS 10
Vancomycin 64 464 464 464
Teicoplanin 4 32 464 64
Daptomycin 1 2 4 4
Dalbavancin 1 16 464 464
Telavancin 0.5 1 2 4
Compound 10 4 4 4 4
M. tuberculosis H37Rv M. tuberculosis TT372
Compound GAS medium P&B medium 7H9 medium 7H9 medium
Rifampicin o0.002 o0.002 o40 o40
Compound 10 20 20 160 160
Abbreviations: GAS, glycerol-alanine-salts; GISA, glycopeptide intermediate S. aureus; MDR, multi-drug resistant; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus
aureus; NARSA, Network of Antimicrobial Resistance in S. aureus; P&B, Proskauer and Beck; VRS, vancomycin-resistant S. aureus. Comparison of efﬁcacy of 10 and vancomycin against a panel of
MRSA and glycopeptide intermediate S. aureus, and MDR S. pneumonia, comparison of efﬁcacy of 10 and commercial antibiotics against a panel of vancomycin-resistant S. aureus from the
Network of Antimicrobial Resistance in S. aureus, and comparison of efﬁcacy of 10 and rifampicin against MDR Mycobacterium tuberculosis H37RV and TT372 strains. The 7H9 medium contains
oleic acid, albumin, dextrose and catalase, which is needed for the growth of the bacteria. GAS medium has a ﬁnal pH of 6.6 and the Proskauer and Beck (P&B) medium has a ﬁnal pH of 7.4. A
full color version of this table is available at The Journal of Antibiotics journal online.
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characteristic MscL channel activities were easily seen, and a signiﬁcant
increase in the probability of channel opening was observed after
treatment with 10. A decrease in the pressure threshold needed to gate
Eco MscL was also observed after 10min incubation with 10
(82.9± 4.3 percentage of the pressure required to gate the untreated,
n= 5, P⩽ 0.02, Student t-test paired). No change in the pressure
threshold required to gate MscS was observed in these patch-clamp
experiments (97.7± 4.9 percentage of untreated, n= 4). As previously
observed, such subtle increases in mechanosensitivity of MscL mutants
in patch-clamp experiments can lead to signiﬁcantly slower bacterial
growth of strains harboring these mutants.9,21
To rule out the possibility that 10 simply disrupts bacterial cellular
membranes at the concentration at which it is effective in the E. coli
growth experiments (shown in Figure 2a, Figure 2b and the patch-
clamp results shown in Figure 2c), we carried out ﬂow cytometry
experiments in which E. coli FRAG-1 expressing Eco MscL treated
with 10 were stained with propidium iodide (PI) (to test for the
intactness of membranes) and SYBR Green I to stain all the cells.
These ﬂow cytometry data revealed that the control sample had
~ 98.5% viability, as determined by the intensity of PI-stained cells
(Figure 2d). As a control, cells were heated to 60 °C for 20min, which
resulted in ~ 57% of the cells being permeable to PI. As shown in
Figure 2d, the integrity of the E. coli FRAG-1 membranes was not
compromised with concentrations of 10 up to ~ 54 μg ml− 1. However,
there was an almost 100-fold decrease in the intensity of the SYBR
Green I as the concentration of 10 increased from ~3.4 to 54 μg ml− 1,
suggesting a signiﬁcant decrease in DNA content as a result of
inhibition of growth and cell division.
Compound 10 causes morphological changes in S. aureus
On the basis of the observations from the patch-clamp experiments
and the titration experiments above, we hypothesized that the
opening of the MscL channel caused by 10 might result in changes
in the size and shape of bacterial cells. Low-magniﬁcation scanning
electron microscopy (SEM) of S. aureus ATCC 6538 showed a
decrease in bacterial density and bioﬁlm formation, concurrent
with an increase in the concentration of 10 (Supplementary
Figure S3). Bacterial size measurements revealed that bacteria treated
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Figure 2 Mechanism of action studies. (a) Titration curve showing the effect of different concentrations of 10 on growth of E. coli MJF612 bacteria carrying
an empty vector (dark blue) or expressing E. coli (Eco) MscL (red), K55T Eco MscL (green), S. aureus (SA) MscL (light blue) or C. perﬁngens (CP) MscL
(orange). Note that the SA MscL data directly overlay the data for the vector-only-negative control. Each OD point presented is the average of four wells and
all experiments are internally controlled. (b) The growth of cultures at stationary phase with or without at 13.5 μgml− of 10 was measured for MJF612
bacteria carrying an empty vector (dark blue) or expressing Eco MscS (purple), Eco MscL (red), K55T Eco MscL (green), SA MscL (light blue) or CP MscL
(orange). Bacterial growth is represented as a percentage of the untreated samples. *P⩽0.0045, **P⩽0.0001, One-way ANOVA and Dunnett’s multiple
comparison test against empty vector. (c) Effect of 10 on MscL channel activity in native bacterial membranes. MscL channel activity was measured before
(top) and after the addition of 25 μgml−1 of 10 to the bath (bottom). Channels were activated by negative pressure applied to the patch. The traces are from
the same patch held at the pressures shown for each trace (bottom left). (d) Flow cytometry data of E. coli (FRAG-1) untreated, heat-treated at 60 °C for
20min and treated with 10 at the designated concentrations. SYBR Green I was used as a DNA-staining agent and propidium iodide was used to detect
membrane porosity. A full color version of this ﬁgure is available at The Journal of Antibiotics journal online.
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with 0.5 μg ml− 1 were signiﬁcantly wider than the control (Figure 3a).
At concentrations of 10 40.5 μg ml− 1, there was a gradual
but signiﬁcant reduction in the size of the bacteria. Moreover,
untreated S. aureus showed a round and ﬁrm geometry with
distinct surface features, which become distorted with increasing drug
concentrations. Atomic force microscopy (AFM) also revealed a
statistically signiﬁcant change in morphology of the uppermost
25 nm region of S. aureus (see Figure 3b for illustration). This region
Figure 3 Microscopic analysis of S. aureus ATCC 29213 treated with 10 at different concentrations. (a) SEM images and size measurements of S. aureus
with an inset showing the mean±95% conﬁdence (n=12). Scale bar 1 μm and magniﬁcation ~×85 000. (b) The change in the ‘a’ parameter (representing
bacteria curvature) is shown with representative 3D AFM images beneath (3 μm×3 μm×700 nm). The top 25 nm of an AFM scan was used as a basis for a
parabolic equation ﬁt y= ax2+bx+c to show the change in curvature after treatment with the drug. The inset shows the mean±95% conﬁdence (n=10 for
1×MBC and n=20 for other concentrations). A full color version of this ﬁgure is available at The Journal of Antibiotics journal online.
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was observed to be of narrow parabolic geometry in the control
sample, which then ﬂattened as the drug concentration increased
(Figure 3b). The AFM and SEM results support each other, as the
latter width measurement is inversely proportional to the measure-
ment of the parabolic curvature parameter ‘a’. These morphological
changes are consistent with the spontaneous activation of MscL in the
presence of 10 leading to solute loss and osmolytes and consequently a
reduction in the size of S. aureus.
Compound 10 is effective in an animal model of S. aureus infection
Compound 10 has potent antibacterial activity in vitro, and accord-
ingly we tested whether this activity would translate to in vivo models
of infection. We examined the efﬁcacy of 10 in treating the nematode
C. elegans infected with MRSA strain MW2. Approximately 60% of the
worms survived when treated with 10 at concentrations above 0.2
μg ml− 1 and490% of the worms survived the MRSA infection at the
most effective concentration of 10, 6.25 μgml− 1 compared with a 5%
survival rate for the control (Figure 4). The range of effective
concentrations (0.2–100 μgml− 1) also corresponded to low bacterial
counts in vitro as detected by measuring the OD at 600 nm (OD600) in
assay wells without the presence of worms.
DISCUSSION
Compound 10 is a potent antibiotic against drug-resistant
Gram-positive bacteria with limited activity against Gram-negative
species. However, it is worth noting that although 10 showed no
apparent effect on E. coli ATCC 25922 (MIC464 μg ml− 1), it did
show an inhibitory effect on the growth of E. coli MJF612
(MIC ~13.5 μg ml− 1) as shown in Figures 2a and b. The difference
in effect is due to a strain variation, being previously observed for a
number of ﬂuoroquinolone antibiotics where in some cases the
difference in susceptibility between the WT and the ATCC
25822 strains was over fourfolds.22 The reduced activity against
Gram-negative bacteria presumably arises from the presence
of the lipopolysaccharide-containing outer membrane, which acts as
a barrier to hydrophobic compounds such as 10. Although 10 kills
bacteria, it is nontoxic to mammalian cells. The lowest concentration
at which any cytotoxicity has been observed in any cell line is 50
μgml− 1, allowing for a tolerated therapeutic window between 4 and
50 μg ml− 1 for MRSA.
We have shown here that, the potency of the antimicrobial activity
of 10 is dependent on MscL. These data are consistent with the in silico
results, suggesting binding of the compound to the channel. 10
represents the ﬁrst success at designing a drug with speciﬁcity to MscL.
Some previous studies suggest that there are other antibacterial
compounds that may have some inﬂuence on the channel; however,
most of these studies did not show both an in vivo dependence upon
MscL expression and a direct effect on channel activity. The bacterial
toxin sublancin 168,23 a glucosylated bacteriocin showed MscL-
dependent activity against Bacillus subtilis and S. aureus in vivo, but
there was no assessment of the role of MscS or any electrophysiolo-
gical studies. Another group of antimicrobial agents (Parabens) has
been reported to affect MscL as assayed by patch-clamp analysis, but
there have been no in vivo studies to determine any MscL-dependent
effects. Parabens affect MscS as well as MscL,24,25 suggesting that they
are nonspeciﬁc activators of membrane-tension-gated channels, as has
been observed for several amphipaths.26,27 Finally, MscL expression
has recently been shown to increase streptomycin potency, and overall
the effects appear to be speciﬁc for MscL, suggesting direct binding;
the open channel may even serve as a route for streptomycin to get
access to the cytoplasm.21 10 affects MscS- as well as MscL-expressing
cells, suggesting it might have some amphipathic or nonspeciﬁc ability
to activate bacterial membrane-tension-gated channels in vivo. How-
ever, in patch-clamp experiments, only MscL showed a decrease in the
pressure threshold in the presence of 10, in agreement with a
facilitation to gate MscL. Hence, the predicted binding of 10
to MscL and the ﬁnding that MscL appears to be more affected than
MscS as assayed by patch-clamp suggests that while there may
be an amphipathic component to MscL activation by 10 in vivo,
there may also be a more MscL-speciﬁc agonist action as well. In
addition, the ﬂow cytometry experiments show that there is no
compromise to the integrity of the plasma membrane, consistent with
the interpretation that 10 directly interacts with the channels. At last,
microscopic imaging using SEM and AFM analysis reveal a signiﬁcant
change in bacterial cell morphology in bacteria treated with 10,
with the bacteria ﬂattened and shrunk, which is consistent with
MscL channel activation. Therefore, these data suggest that MscL is a
target for 10.
In vivo testing of 10 in an MRSA infection model in the nematode
C. elegans has shown that the drug is an active antibiotic, rescuing the
worms from the infection at a concentration of ~ 1.5 μgml− 1
(Figure 4). The worm infection model represents a therapeutic
window from 0.2 to 50 μgml− 1, a range at which no toxicity is
observed in human cell lines. This therapeutic window is better than
that of FDA-approved antibiotics, such as tobramycin and gentamicin
(therapeutic range of 4–10 μgml− 1), amikacin (therapeutic range 20–
30 μg ml− 1) and vancomycin (therapeutic range 20–40 μgml− 1). The
results highlight and address some of the preliminary challenges in
antibiotic development and pave the way for future research and
development for the antimicrobial compounds discussed herein,
including resistance emergence testing, formulation of 10 and analogs
thereof, in addition to investigating different routes of administration
using different animal infection models.
METHODS
In silico design experiments
Autodock 3.0528 was used for the in silico docking experiments as it is well
































Figure 4 Percentage of surviving C. elegans as a function of 10
concentration and density of surviving bacteria as a function of 10
concentration in the absence of C. elegans. The percentage of worm survival
is shown in red with the corresponding axis on the right and the growth of
MRSA MW2 is shown in blue with the corresponding axis on the left.
Concentrations are shown in μgml−1. The negative control with solvent
DMSO is shown on the far left and the positive control with antibiotic
vancomycin is shown on the far right. A full color version of this ﬁgure is
available at The Journal of Antibiotics journal online.
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to use. The atomic coordinates of the MscL protein from E. coli were obtained
from a homology structure designed previously.29 In this structure, the amino-
acid residues of M. tuberculosis have been replaced with those of E. coli and the
coordinates of the amino acids left unaltered. The Eco MscL structure used is a
truncated version of MscL and has only 95 amino-acid residues (Met12 to
Glu107), compared with the 136 amino-acid residues representing the whole
protein. Past experiments suggest that the rest of the protein is not signiﬁcant
for the activity of MscL and therefore removing it was advantageous by saving
computer power and signiﬁcantly reducing the computational time. The
Protein Data Bank ﬁle of the Eco MscL was loaded in Autodocktools and
the water molecules removed. Polar hydrogens were added to the proteins and
the charges and solvation parameters were added to the atoms of the
macromolecule, and the ﬁle saved in Protein Data Bank ﬁle format with
charges and solvation parameters included.
The ligands were built and saved in Brookhaven format30 and Autodocktools
was used to prepare the ligands for docking. The rigid root of the ligand was
deﬁned automatically and the maximum number of rotatable bonds was
allowed. The number of active torsions was set to the number of rotatable
bonds and the toggle activity of torsions allowed to move most atoms. The
partial atomic charges were calculated31 using the AM1 Hamiltonian, and the
geometry of the ligand was optimized. These were entered into the Protein Data
Bank ﬁle replacing the charges generated using Autodocktools.
The grid size and center used for the Autodock calculation (see
Supplementary Table S1 for parameters used for docking) was restricted to
the amino-acid residues near Ala20, as it has been shown that this is where
parabens and eriochrome cyanine bind.24 To narrow down the search for target
amino acids, the amino acids that surround the docked ligands were
determined. The amino-acid residues surrounding the ligands for most of
the dockings ranged from Leu19 to Lys31. Hydrogen acceptor groups (namely
oxygen atoms) were targeted in the protein side chain. Depending on where
they occur, a ligand with hydrogen donor groups was then designed that can
H-bond with the oxygen atoms. This approach was taken given that there were
a limited number of amino acids with oxygen atoms exposed to the inside of
the pore. This identiﬁed amino acids, Leu19, Ala20, Val23, Gly26 and Ala27,
with oxygen atoms exposed to the inside of the pore. The oxygen atoms in
Gly26 and Ala27 are slightly shielded by other amino acids. In addition, they
point to the side rather than to the inside of the pore, and hence may not
contribute signiﬁcantly to hydrogen bonding.
It is also important to note that the geometry of these ﬁve amino acids is the
same in the ﬁve subunits, as long as no more than one amino acid is considered
to be in any subunit. Therefore, instead of visualizing these amino acids in one
chain, they were visualized as an amino acid/subunit so that subunit 1 has
Leu19, subunit 2 has Ala20, subunit 3 has Val23, subunit 4 has Gly26 and
subunit 5 has Ala27.
As parts of the protein pore are narrower than others, it was important to
design a pharmacophore that has a length less than the diameter of the pore at
the position of all ﬁve amino-acid residues. If this is the case, then any one
pharmacophore will, at most, bind to four amino acids. Owing to the fact that
the most accessible oxygen atoms are in the following amino acids: Leu19,
Ala20 and Val23, particular attention was given to these amino acids.
A de novo approach was undertaken to design a pharmacophore and
seven ligands were constructed with three hydroxyl groups each (Figure 1a).
These ligands were then docked with the Eco MscL. The assumption being
that the closer the hydroxyl groups of a ligand to the spatial dimensions of the
ketone groups in Eco MscL (Supplementary Table S2), the better the docking.
This was not the case; nonetheless, the results showed exceptional docking
energies for ligand 2, which was then used as a lead in an iterative docking
process.
The hydroxyl groups in ligand 2 were replaced by various functional
groups and the effect on docking energy was noted. The functional
groups include: aldehydes, amide cations, amino, carboxyl and chlorines
(Figure 1c). The carboxyl groups were deprotonated and were added, one at
a time, until the carboxyl groups replaced all the hydroxyl groups. The four
phenyl groups of ligand 2 were also replaced by cyclohexane groups. The parent
compound was also included (which did not include the hydroxyl groups).
The best docking energy was observed with replacement of all hydroxyl
groups for carboxyl groups with an overall charge of − 3 on the molecule.
This ligand has an exceptional free energy of binding equivalent to ~− 55.94
kJmol− 1, which is higher than that previously reported.6 MscL may not show
an overall ion selectivity; however, the docking results show preferential binding
to the mostly hydrophobic deprotonated tri-acid species.
Compound 10 synthesis
Drug synthesis was carried out using a procedure published previously32 with
some modiﬁcations. Ethyl acetate (20%) in hexane was used for monitoring the
progress of the Heck cross-coupling reaction using thin layer chromatography
and 20:80 ethyl acetate-dichloromethane for eluting the product using ﬁne
silica after tetrahydrofuran removal under vacuum. The product from the
saponiﬁcation reaction was collected by ﬁltration and eluted in ﬁne silica using
a 20:80 methanol-tetrahydrofuran solvent system, followed by the addition of
diethyl ether as an anti-solvent to wash the compound.
MIC assay
All compounds were prepared at 160 μgml− 1 in water from a stock solution of
20mM of 10 in dimethyl sulfoxide (DMSO). The compounds, along with
standard antibiotics, were serially diluted twofold using Mueller Hinton broth
(MHB) in 96-well plates (nonbinding surface, Corning 3641, Tewksbury, MA,
USA) using MHB. Concentrations of standards ranged from 64 μg ml− 1 to
0.03 μgml− 1, and concentrations of compounds ranged from 8 to 0.003
μgml− 1, with ﬁnal volumes of 50 μl per well. Gram-positive bacteria were
cultured in MHB (Bacto Laboratories Pty Ltd, Mt Pritchard, NSW, Australia) at
37 °C overnight. Mid-log phase bacterial cultures were diluted to the ﬁnal
concentration of 5× 105 CFUml− 1 (in MHB) and used with the diluted
compounds to be tested. Plates were covered and incubated at 37 °C for 24 h,
and MICs designated as the lowest concentration that showed no visible
growth. Experiments were carried out in duplicate (n= 2), with vancomycin as
a positive inhibitor control.
M. tuberculosis testing
Rifampicin and 10 were resuspended in DMSO and diluted to obtain a drug
concentration of 160 μgml− 1. Five microliter of this drug concentration
(equivalent to 0.8 μg) was dispensed into a 96-well plate and serially twofold
diluted in DMSO (ﬁnal drug volume 5 μl). Thereafter, frozen aliquots of the
bacterial strains H37Rv and Victor strain TT372 were thawed and suspended at
2× 105 bacteria per ml in 7H9 media supplemented with oleic acid, albumin,
dextrose and catalases (ﬁnal albumin concentration of 5 g l− 1). Two hundred
microliter of these bacterial suspensions were added to each well in 96-well
plates, containing either compound (ﬁnal drug concentration: 4 μgml− 1).
Plates were incubated at 37 °C for 7 days, when 20 μl of Alamar Blue reagent
were added to each well. Plates were incubated for an additional 2 days at 37 °C,
when absorbance was evaluated in a microtiter plate reader at 570 nm. Bacterial
absorbance was normalized to the blank absorbance and compared with the
positive control (untreated bacteria). Data were graphed as percent inhibition.
A similar procedure was carried out for M. tuberculosis H37Rv grown in
glycerol-alanine-salts medium and Proskauer and Beck medium at a pH 7.4. At
concentration ⩾ 80 μgml− 1, 10 precipitated in glycerol-alanine-salts medium
pH 6.6. However, no precipitation was observed at lower concentrations (40–
5 μgml− 1) where it also inhibited bacterial growth.
NIH/3T3 and HaCaT cytotoxicity assay
HaCaT immortalized keratinocytes and NIH/3T3 ﬁbroblasts were seeded as
1.5 × 103 cells per well in a 96-well plate in 50 μl media (Dulbecco’s modiﬁed
Eagle’s medium/F12+GlutaMAX from Gibco (Mulgrave, VIC, Australia) with
10% v/v foetal bovine serum and 1% v/v penicillin/streptomycin). Cells were
incubated for 2 h at 37 °C, 5% CO2 to allow cells to attach to the plates. 10 was
prepared in DMSO and diluted 20 times in culture media, giving a ﬁnal
concentration of 1mgml− 1 with 5% DMSO. Fifty microliter of each dilution
was added into 50 μl of culture medium in triplicates to reach the ﬁnal
concentrations. The cells were incubated with the compounds overnight at
37 °C, 5% CO2. After the incubation, MTS(3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt)
(Promega, Australia, Alexandria, NSW, Australia) (60 μl) was added to each
well. The plates were then incubated for 3 h at 37 °C, 5% CO2. Sixty microliter
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from each well was transferred to a new plate and the absorbance was then read
at 490 nm using EnSpire 2300 Multimode Plate Reader. Results are presented as
the average percentage of control± s.d. for each set of duplicate wells. The
difference between the experiment and the blank is recorded as normalized
mean. For each treatment, the experiment was carried out in triplicate for each
time point, at 0, 24, 48 and 72 h. Time 0 starts after overnight incubation.
HepG2 and HEK293 cytotoxicity assay
10 was prepared in DMSO at 20mM. It was diluted 200 times in culture media,
giving a ﬁnal concentration of 50 μgml− 1 with 0.5% DMSO. Hepatocellular
carcinoma (HepG2 ATCC HB-8065) and human embryonic kidney cells
(HEK293 ATCC CRL-1573) cells were seeded as 1.5 ×104 cells per well in a
96-well plate in a ﬁnal volume of 100 μl in Dulbecco’s modiﬁed Eagle’s medi
(Gibco-Invitrogen, Waltham, MA, USA), in which 10% or 1% of foetal bovine
serum was added. Cells were incubated for 24 h at 37 °C, 5% CO2 to allow cells
to attach. All tested compounds were diluted from 2.5mgml− 1 to 0.38 μgml− 1
in threefold dilutions. Then, 10 μl of each dilution was added into 90 μl of
culture medium in triplicates. Colistin and Tamoxifen were used as the controls.
The cells were incubated with the compounds for 24 h at 37 °C, 5% CO2. After
the incubation, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(Invitrogen) was added to each well to a ﬁnal concentration of 0.4mgml− 1. The
plates were then incubated for 2 h at 37 °C, 5% CO2. Medium was removed, and
crystals were resuspended in 60 μl of DMSO. The absorbance was then read at
570 nm using a Polarstar Omega instrument. The data were then analyzed by
Prism software. Results are presented as the average percentage of control± s.d.
for each set of duplicate wells using the following equation: Percent viability=
(ABSTEST−ABS5%DMSO/ABSUNTREATED−ABS5%DMSO)×100.
Strains and cell growth
Constructs were inserted in the PB10d expression vector9,33–35 and the E. coli
strain MJF612, which is null for MscL, MscS and MscS homologs (FRAG-1
ΔmscL::cm, ΔmscS, ΔmscK::kan, ΔybdG::aprΔ)17 were used as a host for all
experiments. Unless stated otherwise, cells were grown in citrate-phosphate
deﬁned medium consisting of (per liter: 8.57 g of Na2HPO4, 0.87 g of K2HPO4,
1.34 g of citric acid, 1.0 g of NH4SO4, 0.001 g of thiamine, 0.1 g of
Mg2SO4.7H2O, 0.002 g of (NH4)2SO4.FeSO4.6H2O) plus 100 μgml− 1
ampicillin.
In vivo growth inhibition experiments
E. coli strain MJF612 was used as a host for Eco MscL (MscL), K55T Eco MscL
(K55T MscL), C. perfringens MscL, SA MscL and E.coli MscS (MscS) constructs
in the PB10d expression vector. Overnight cultures were grown in citrate-
phosphate deﬁned medium pH 8 plus 100 μgml− 1 ampicillin with shaking at
37 °C. The following day, cultures were diluted 1:40 in the same media and
grown for 30min before inducing expression with 1mM isopropyl β-D-1-
thiogalactopyranoside. After 30min of induction, all cultures were adjusted to
an OD600 of 0.08. The cultures were then diluted 1:3 into pre-warmed citrate-
phosphate deﬁned medium pH 8 containing 100 μgml− 1 ampicillin plus 10.
Cultures were loaded in 96-well plates (190 μl per well), sealed with a
breathable ﬁlm, and incubated at 37 °C for 16 h without shaking. The OD595
of the cultures was measured using a Multiskan Ascent (Thermo Scientiﬁc Inc.,
Waltham, MA, USA).
Electrophysiology
E. coli giant spheroplasts were generated as previously described20 from PB104
strain (ΔmscL::Cm)34 expressing Eco MscL. Patch-clamp experiments were
performed in the inside–out conﬁguration, at room temperature under
symmetrical conditions in a buffer at pH 6.0 (200mM KCl, 90mM MgCl2,
10mM CaCl2 and 5mM HEPES). Patches were excised, and recordings were
performed at 20 mV (for simplicity the patch traces openings are shown
upward). Data were acquired at a sampling rate of 20 kHz with 10 kHz ﬁltration
using an AxoPatch 200B ampliﬁer (Molecular Devices, Sunnyvale, CA, USA). A
piezoelectric pressure transducer (World Precision Instruments, Sarasota, FL,
USA) was used to measure the pressure throughout the experiments. After
taking three separate pressure threshold measurements in regular patch buffer
for control, a 25 μgml− 1 solution of 10 was perfused to the bath and channel
sensitivity within the same patch was measured subsequently every 10min.
Flow cytometry experiments
Bacterial cultures were prepared from a single colony of E. coli FRAG-1 grown
on Lysogeny Broth media. The single colony was added to 8.5 ml of ﬁltered
MHB (0.2 μM Minisart, Sartorius Stedim) to which 10 (3.375 μgml− 1 to 54
μgml− 1 in doubling concentrations) was added. The cultures were incubated
overnight at 37 °C with shaking in 2ml volumes before analysis, at which point
SYBR Green I (10×ﬁnal in MHB) and PI (10 μgml− 1 ﬁnal in H2O) were
added. Cells were incubated for 5 min, prior to analysis. The heat-treated
sample was exposed to 60 °C for 20min before adding SYBR Green I and PI
and incubated for 5 min.
An Accuri C6 Flow Cytometer was used for the ﬂow cytometer experiments.
The ﬂuidics rate was set to Medium (35 μl min− 1) and the threshold limit was
set on FL1 (530/30) to a value of 800. Samples were run and 30 000 events
collected. Sample data were analyzed using the CFlow software. FL2-A (585/60)
(Emmax 605 nm, PI) was plotted on the y axis versus FL1-A (530/30) (Emmax
521 nm, SYBR Green I) on the x axis. No gates were applied and ﬂuorescence
compensation was not required.
Sample preparation for microscopy
The bacterial strain S. aureus ATCC 6538 was grown overnight at 37 °C on
Muller–Hinton Agar (Oxoid, Thermo Fisher Scientiﬁc Inc., Waltham, MA,
USA). The bacteria were harvested and the OD of bacteria suspended in MHB
was adjusted to ~ 0.5 MacFarlane units so as to give 5× 107 CFUml− 1. Bacteria
were then aliquoted into 10ml tubes and various amounts of 10 at 1 mgml− 1
dissolved in DMSO were added to give a ﬁnal concentration ranging from
32 μgml− 1 to 0.5 μgml− 1 (twofold serial dilutions). Bacterial numbers were
enumerated using the Miles–Misra method in which serial dilutions of 10 μl
samples from each culture were spread onto nutrient agar in duplicate. After
incubation at 37 °C for 24 h, the colonies were counted.
S. aureus ATCC 6538 cultures were treated as above and incubated overnight.
Cultures were loaded into sterile disposable syringes and ﬁltered through a
0.2-μm isopore polycarbonate hydrophilic ﬁlter (Millipore, Billerica, MA,
USA). Bacteria on ﬁlters were ﬁxed in 4% paraformaldehyde/1.25% glutar-
aldehyde in phosphate-buffered saline and 4% sucrose (pH 7.2) for 15min.
The ﬁxative was removed with a sterile pipette and the ﬁlters washed in a
washing buffer composed of 4% sucrose in phosphate-buffered saline for
5min. The washing buffer was then removed and the bacteria were post-ﬁxed
in 2% OsO4 in water for 30min. The OsO4 were then pipetted out into an
osmium waste bottle and the bacteria were washed in a washing buffer
composed of 4% sucrose in phosphate-buffered saline for 5 min. The bacteria
were then dehydrated in four consecutive different concentrations of ethanol,
70% ethanol (1 change of 10min), 90% ethanol (1 change of 10min), 95%
ethanol (1 change of 10min) and 100% ethanol (3 changes of 10min). After
removing the ethanol, the bacteria were critical point dried in hexamethyldi-
silazane (2 changes of 15min) and then mounted on a stub and platinum
coated (10 nm). Carbon paint was then applied to the edges of the stub making
contact with the ﬁlter to improve conductivity and reduce sample charging.
Scanning electron microscopy analysis
SEM was carried out using a FEG Quanta 450 microscope at an accelerating
voltage of 3–7 Kv and a working distance of 10mm. The specimens were
observed using a secondary electron detector under high-vacuum conditions.
Images were captured at high deﬁnition at ~×85 000 magniﬁcation and a scan
rate of 100ms per frame.
Atomic force microscopy analysis
AFM images were acquired in air using a Bruker Dimension FastScan AFM
with a Nanoscope V controller, operating in PeakForce Tapping mode. Bruker
ScanAsyst Air probes with a nominal tip radius of 2 nm and nominal spring
constant of 0.4 Nm− 1 were used. Imaging parameters including set-point, scan
rate (1–2Hz) and feedback gains were adjusted to optimize image quality and
minimize imaging force. Images were analyzed using the Bruker Nanoscope
Analysis software (version 1.4). The AFM scanner was calibrated in the x, y and
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z directions using silicon calibration grids (Bruker model numbers PG: 1 μm
pitch, 110 nm depth and VGRP: 10 μm pitch, 180 nm depth).
After acquiring the images, 20 bacteria per sample were chosen at random
and a cross-section was drawn through the apex of each bacteria. The shape of
the uppermost 25 nm of each bacteria was analyzed by ﬁtting the parabolic
function y= ax2+bx+c, and extracting the coefﬁcient ‘a’, which represents the
curvature of the parabola. Higher ‘a’ values describe a narrow apex geometry,
whereas low ‘a’ values describe a ﬂatter apex with lower curvature. The analysis
was restricted to the uppermost 25 nm in order to ensure that all of the samples
were analyzed in the same manner, as many of the bacteria are embedded in
organic matter to varying degrees, which restricts the analysis region in
each case.
C. elegans infection model
The C. elegans infection assay was carried out as previously described.36 A stock
solution of 10 in DMSO (10mgml− 1) was prepared. Dilution series consisting
of 1:10 dilution (from 100 μgml− 1) and a 1:2 dilution (from 100 μgml− 1)
were tested. To prepare a 1:10 dilution series, 5 μl of 100 μgml− 1 of 10 was
diluted into 45 μl of liquid media with 1% DMSO. This was repeated for all
dilutions. To each well, 20 μl of compound containing liquid media was added
followed by the addition of 35 μl of MRSA and 15 μl media containing 15
worms. Vancomycin at 20 and 100 μgml− 1 were used as positive controls and
DMSO was used as a negative control. After infection and co-incubation with
compound for 4 days, bacteria were washed out and the worms were stained
with Sytox Orange dye and imaged. The ratio of stained to unstained worm
area was used to measure worm death. Prior to washing, an OD600
measurement was taken to assess the bacterial growth.
Full methods and any associated references are available in the online version
of the paper at www.nature.com/nature.
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